CASTLE BIOSCIENCES INC (CSTL) — SEC Filings

Latest SEC filings for CASTLE BIOSCIENCES INC (CSTL), explained in plain English.

Sentiment Overview: 2 bearish, 25 neutral

Recent Filings (27)

• Castle Biosciences Files 2025 Annual Report — ARS · 2026-04-08T10:14:54-04:00 [neutral] Risk: low
  Castle Biosciences Inc. filed an Annual Report to Security Holders (ARS) on April 8, 2026, for the period ending December 31, 2025. The filing includes a comple
• DEFA14A Filing — DEFA14A · 2026-04-08T10:13:57-04:00 [neutral]
• Castle Biosciences Swings to Loss Amid Soaring Amortization Costs — 10-Q · 2025-11-03T00:00:00.000Z [bearish] Risk: high
  CASTLE BIOSCIENCES INC reported a net loss of $501 thousand for the three months ended September 30, 2025, a significant decline from a net income of $2.269 mil
• Castle Biosciences Amends Articles of Incorporation — 8-K · 2025-08-08T00:00:00.000Z [neutral] Risk: low
  Castle Biosciences, Inc. filed an 8-K on August 8, 2025, reporting an amendment to its Articles of Incorporation, effective August 5, 2025. This filing indicate
• Castle Biosciences' Q2 Loss Widens to $28.1M Amid R&D Push — 10-Q · 2025-08-04T00:00:00.000Z [bearish] Risk: high
  CASTLE BIOSCIENCES INC reported a net loss of $28.1 million for the three months ended June 30, 2025, a significant increase from the $20.5 million net loss in
• Castle Biosciences Files 8-K on Security Holder Rights & Corporate Actions — 8-K · 2025-05-23T00:00:00.000Z [neutral] Risk: medium
  On May 22, 2025, Castle Biosciences, Inc. filed an 8-K report detailing several key events. These include material modifications to the rights of security holde
• Castle Biosciences Q1 2025 10-Q Filed — 10-Q · 2025-05-05T00:00:00.000Z [neutral] Risk: medium
  Castle Biosciences Inc. filed its 10-Q for the period ending March 31, 2025. The filing details financial performance and operational updates for the first quar
• Castle Biosciences DEF 14A Filing Details Executive Compensation — DEF 14A · 2025-04-09T00:00:00.000Z [neutral] Risk: low
  Castle Biosciences Inc. filed its DEF 14A on April 9, 2025, for the fiscal year ending December 31, 2024. The filing details executive compensation and other co
• Castle Biosciences Files 2024 10-K — 10-K · 2025-02-27T00:00:00.000Z [neutral] Risk: medium
  Castle Biosciences Inc. filed its 2024 10-K on February 27, 2025, reporting on its fiscal year ending December 31, 2024. The company, headquartered in Friendswo
• Castle Biosciences Files 8-K on Financials — 8-K · 2025-01-13T00:00:00.000Z [neutral] Risk: low
  Castle Biosciences, Inc. filed an 8-K on January 13, 2025, reporting on its results of operations and financial condition as of January 12, 2025. The filing als
• SC 13G/A Filing — SC 13G/A · 2024-11-14T00:00:00.000Z [neutral]
• SC 13G/A Filing — SC 13G/A · 2024-11-13T00:00:00.000Z [neutral]
• Castle Biosciences Files Q3 2024 10-Q — 10-Q · 2024-11-04T00:00:00.000Z [neutral] Risk: medium
  Castle Biosciences Inc. filed its 10-Q for the period ending September 30, 2024. The filing details financial performance and operational updates for the third
• Castle Biosciences Files Q2 2024 10-Q — 10-Q · 2024-08-05T00:00:00.000Z [neutral] Risk: medium
  Castle Biosciences Inc. filed its 10-Q for the period ending June 30, 2024. The filing details financial performance and operational updates for the second quar
• SC 13G/A Filing — SC 13G/A · 2024-07-08T00:00:00.000Z [neutral]
• Castle Biosciences Reports on Shareholder Vote Outcome — 8-K · 2024-05-24T00:00:00.000Z [neutral] Risk: low
  Castle Biosciences, Inc. filed an 8-K on May 24, 2024, reporting on a matter submitted to a vote of its security holders on May 23, 2024. The filing details the
• Castle Biosciences Files Proxy Statement Update — DEFA14A · 2024-05-10T00:00:00.000Z [neutral] Risk: low
  Castle Biosciences, Inc. filed a DEFA14A on May 10, 2024, which is a definitive additional material related to their proxy statement. The filing concerns the co
• Castle Biosciences Inc. Files 10-Q for Period Ending March 31, 2024 — 10-Q · 2024-05-02T00:00:00.000Z [neutral] Risk: medium
  CASTLE BIOSCIENCES INC (CSTL) filed a Quarterly Report (10-Q) with the SEC on May 2, 2024. Castle Biosciences Inc. filed a 10-Q report for the period ending Mar
• Castle Biosciences, Inc. 2024 Annual Meeting of Stockholders Proxy Statement — DEF 14A · 2024-04-10T00:00:00.000Z [neutral] Risk: low
  CASTLE BIOSCIENCES INC (CSTL) filed a Proxy Statement (DEF 14A) with the SEC on April 10, 2024. Castle Biosciences, Inc. will hold its 2024 Annual Meeting of St
• Castle Biosciences Appoints New Chief Medical Officer — 8-K · 2024-03-27T00:00:00.000Z [neutral] Risk: medium
  Castle Biosciences, Inc. announced on March 26, 2024, the departure of its Chief Medical Officer, Dr. Derek J. Maathuis. The company also announced the appointm
• Castle Biosciences Inc. Files 2023 Annual Report on Form 10-K — 10-K · 2024-02-28T00:00:00.000Z [neutral] Risk: medium
  CASTLE BIOSCIENCES INC (CSTL) filed a Annual Report (10-K) with the SEC on February 28, 2024. Castle Biosciences Inc. filed its 10-K report for the fiscal year
• SC 13G Filing — SC 13G · 2024-02-14T00:00:00.000Z [neutral]
• SC 13G Filing — SC 13G · 2024-02-13T00:00:00.000Z [neutral]
• SC 13G/A Filing — SC 13G/A · 2024-02-13T00:00:00.000Z [neutral]
• Wasatch Advisors LP Holds 9.6% Stake in Castle Biosciences — SC 13G/A · 2024-02-09T00:00:00.000Z [neutral] Risk: low
  Wasatch Advisors LP, an investment adviser based in Salt Lake City, Utah, has updated its ownership stake in Castle Biosciences Inc. (CSTL) to 2,590,951 shares
• BlackRock Amends Castle Biosciences Stake to 9.2% — SC 13G/A · 2024-01-25T00:00:00.000Z [neutral]
  BlackRock Inc. filed an amended SC 13G/A on January 25, 2024, disclosing its ownership in Castle Biosciences Inc. As of December 31, 2023, BlackRock beneficiall
• Castle Biosciences Files 8-K on Financial Condition & Operations — 8-K · 2024-01-08T00:00:00.000Z [neutral]
  Castle Biosciences, Inc. filed an 8-K on January 8, 2024, reporting an event that occurred on January 7, 2024. This filing indicates that the company is providi